Chemotherapy TIP

Phase 2Small molecule

UUNICANCER

Chemotherapy TIP is one of 51 small molecule programs targeting Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell CarcinomaActive, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

69 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

21 2

Erbitux

IImclone

Phase 3

45 3

Opdivo

Bristol-Myers Squibb

Phase 3

14 4

Taxol

Teva

Phase 3

12 5

Paraplatin

AAvyxa

Phase 3

21 6

Tecentriq

Roche

Phase 3

6 7

Libtayo

Regeneron

Phase 3

5 8

Yervoy

Bristol-Myers Squibb

Phase 3

4 9

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Squamous Cell Carcinoma

NCT02817958

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Active, not recruiting·UUNICANCER·Phase 2·NCT02817958·37 enrolled

Breast Cancer1 trial

Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial

Completed·UUNICANCER·Phase 3·NCT01564056·1,989 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Chemotherapy TIP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy TIP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy TIP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNICANCER company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUNICANCER

Chemotherapy TIP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News